Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Bevacizumab beyond progression has been proven to be safe in the community setting (BRiTE)
and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first
line with all regimens of chemotherapy. A total of 1,953 patients were treated in BRiTE. At
median follow-up of 17.5 mo, there were 1,369 1st PD and 839 deaths. Among patients with 1st
PD, 65.2% received any 2nd-line chemotherapy, 34.8% received cetuximab, and 53.8% received
BBP. In a multivariate analysis, Bevacizumab beyond first progression and exposure to any
2nd-line chemotherapy were independently associated with increased overall survival (both p <
0.0001). Bevacizumab beyond progression appears to be associated with longer overall in
BRiTE.
The investigators planned a prospective study to prove this phenomenon of bevacizumab beyond
progression.